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Governance in the
European Union:
The European Blood
Directive as an
Evolving Practice
Hannes Hansen-Magnusson, MA
This article reconstructs governance practices related to blood policy that have devel-
oped within in the European Union (EU) over the last 15 years. It describes core
aspects of the policy and argues that, despite an integrated cooperative approach
between policy-makers and practitioners, this policy remains an open and evolving
process. The European Blood Directive (2002/98/EC) and its subsequent directives
managed, for the first time, to create an overarching framework for transfusion proce-
dures. This framework consists of a number of standard definitions as well as detailed
standard operating procedures (SOPs), yet leaves room for interpretation and different
practices between EU member states. A recently published report on the progress of
transposition of the Directives into national legislation reveals different standards, sug-
gesting a lack of uniformity of safety and quality requirements. Further, gaps in the
directives amount to practical medical problems, while increased mobility among
EU citizens may add further problems to achieving the objective of a self-sufficient
supply of blood and blood products. This might undermine public confidence in the
quality of blood products and the health protection of donors, which, in turn, must
be countered by a cooperative effort of policy-makers and blood establishments.
Blood policies have been on the agenda of the European Community for more than
15 years. They pertain to both qualitative as well as quantitative issues; that is,
assuring the quality and safety of blood and its derived products while simultaneously
ensuring its availability in sufficient quantities. As early as 1994, the European
Commission identified the need for a comprehensive strategy.1,2 Voluntary, unpaid
donations were meant to ensure self-sufficiency in blood and plasma, for which the
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Commission needed to learn about European citizens’ perception and understanding
of blood-related issues as well as citizens’ attitude toward donating.
A survey among citizens of the EU revealed that ‘‘citizens are reasonably well-
informed about general blood issues but several misconceptions do exist reflecting
the need for further information and education programs about blood and plasma
donation.’’3 To this end, the report was meant to ‘‘be of value to national health author-
ities, blood collection and transfusion organizations, blood donor associations, and
the plasma products industry in their efforts to contribute to achieving the goal of
Community self-sufficiency in blood and plasma.’’3
The remainder of this article specifies how these objectives were meant to be
achieved—yet how they remain an unfinished process. To this end, the article details
the content of the European Blood Directive and some of its subsequent specifications
that were meant to build an overarching framework across EU member states. It then
sets out to analyze a recently published report on the transposition progress of the
directives into national legislation. The report reveals that differences continue to exist
between member states on a number of factors. Further problems on the road toward
a safe and self-sufficient supply stem from gaps in the directives, causing medical
problems, as well as from (potential) social and political developments. From these
considerations, it can be concluded that despite the creation of blood directives at
the EU level, the governance of blood remains an ongoing process and a site of
construction.
BLOOD POLICY IN THE EU: DEVELOPING DIRECTIVE 2002/98/EC
In the aftermath of the 1995 survey, a concerted effort to ensure sufficient supplies
was brought under way. It developed in cooperation between the European Commis-
sion as the authoritative norm-setter as well as the European Blood Alliance (EBA) that
was founded in autumn 1998. The EBA consists of members ‘‘with a spectrum of orga-
nization arrangements ranging from the centrally managed national services (.) to
local and regional services.’’4 Their aim is to increase awareness in the public and
among professionals as to the non-remunerated donation of blood and the prepara-
tion of its components for therapeutic purposes; to provide technical and professional
support to members; and to develop facilities for and coordinate information-sharing
on a national, European, and global level. In 2006, blood donations from EBA
members’ blood services amounted to around 15.5 million donations from a popula-
tion of just over 300 million people.4 For comparison, there were approximately 9.6
million allogeneic blood donors in the United States in the same year.5 In the mean-
time, the EBA commented on and contributed expert advice to the European Blood
Directive (EC/2002/98).
Directive 2002/98/EC and its Successors
The Blood Directive from 2002 was the first and groundbreaking attempt to devise
uniform standards of quality and safety for human blood and its components. It did
so by defining minimum safety criteria with a view to contributing to public confidence
in terms of the quality of blood and blood products, as well as health protection of the
donors. In line with the initial objectives of 1994, further intentions were to attain self-
sufficiency and enhance confidence in the safety of the transfusion chain. The direc-
tive is binding for member states of the EU but it leaves open the choice of form and
methods to comply, which includes the possibility of introducing more rigorous stan-
dards. Directive 2002/98/EC is termed the Mother Directive because it functions as
a standard-setter while triggering further, more specific directives.
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Following 2002/98/EC were three further directives that set out technical implemen-
tation measures for issues identified in the Mother Directive. Directive 2004/33/EC
pertained to technical requirements for blood and blood components. Directive
2005/61/EC specified traceability requirements and requirements for the notification
of serious adverse reactions and events. Finally, Directive 2005/62/EC provided stan-
dards and specifications relating to a quality system for blood establishments, similar
to those established by the American Association of Blood Banks in the United
States.2 As Listl and Klouche1 note, these directives were vital for the harmonization
of European blood and blood-component comparability as well as transfer within
Europe because they provided a catalog of definitions that did not exist previously.
Either central terms were not clearly defined, or regulations did not exist in some
member states.
An example of the specificity is provided by Seidl and colleagues2with regard to the
quality system entailed in the Mother Directive and Directive 2005/62/EC. Regarding
the former, they list the description of the quality system to include:
1. An organization chart, including responsibilities of responsible persons and report-
ing relationships
2. A site master file or quality manual describing the quality system in accordance with
Article 11(1)
3. Number and qualifications of personnel
4. Hygienic provisions
5. Premises and equipment
6. List of SOPs for:
Donor recruitment
Retention and assessment of donors
Processing and testing
Distribution and recall of blood and blood components
Reporting and recording of serious adverse reactions and events.
Specifications
On this basis, Directive 2005/62/EC sets out standards and specifications for blood
establishments to ensure the safety of blood across Europe. Guidelines for a quality
system were developed by a multinational project under the leadership of the German
Red Cross Donor Service of Baden-Wu¨rttemberg. The project entailed a consortium of
sixteen members and established a project platform on the implementation of good
practice. It developed a common format and regulations for SOPs to carry out an
activity to demonstrate compliance with procedures,2,6 supported by the EBA.
In the absence of absolute criteria, the quality management system developed is
hierarchically structured in seven steps. They range from the framework of regulations
via guidelines on document change control and personnel training to SOPs that are
simple and user-friendly, listing precise quality requirements, requisites, and quality
terms linked to the EU directives. At the same time, these standards cross-reference
with or exist in addition to processes based on good manufacturing practice, good
laboratory practice, and International Organization for Standardization (ISO) norms
because blood establishments vary in size and often comprise several production
sites. Such nexus of procedural regulations enables the compatibility of sites and
eases exchange of supplies to external sites. The authors conclude that there is
a list of benefits that includes:
- the definition of an overall quality policy
- improved personnel responsibility, qualification and training
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- error and risk assessment system
- continuous improvement
- improved resource management
- performance improvement.2
Although the implementation process of quality control is complex, a positive cost
effect is expected in the mid- to long-run, particularly if synergetic effects between the
EU directives and good manufacturing practice and ISO standards can be
exploited.2,6
THE IMPLEMENTATION PROCESS
In the run-up to a meeting of the competent blood authorities, attendees were asked
to answer a ‘‘questionnaire on the transposition and implementation of the European
regulatory framework of blood and blood components.’’7 It was prepared before
a meeting of competent blood authorities on January 29, 2009, comprising of EU
member states, candidate countries (Croatia, Former Yugoslav Republic of
Macedonia, and Turkey), and European Free Trade Association countries (Iceland,
Liechtenstein, Norway, and Switzerland). The questionnaire was intended to deter-
mine whether countries had indeed transposed the four Directives into national law,
reasons for a delay, and details regarding selected further issues. The report provides
detailed information on:
- the national blood authority (name and address of national authority)
- transposition (has the transposition process been completed?)
- authorization (how many blood establishments are there in the country?)
- hospital blood banks (how many are there in the country?)
- inspections (is a system in place, how many inspections have been performed?)
- donor eligibility criteria (regarding exemption in accordance with Annex III.2.2.2 of
Directive 2004/33/EC) (Annex III.2.2.2 of Directive 2004/33/EC: ‘‘Persons whose
sexual behavior puts them at high risk of acquiring severe infectious diseases that
can be transmitted by blood.’’)
- vigilance (serious adverse events and reactions)
- testing requirements
- imports and exports of blood and blood components
- sanctions (have authorizations been revoked or suspended, or have penalties
been imposed?)
- others (eg, difficulties encountered in the transposition process).
The report may conclude the transposition process of the Directives but, based on
the analysis of answers provided, it still leaves possibility for improving the safety of
blood and blood derivates across Europe. On one hand, not all countries participating
in the meeting in January 2009 provided full information on the sections above. At the
time of publication on January 15, 2010 some empty spaces still had not been filled.
This includes candidate and European Free Trade Association countries that are not
obliged to comply with the Directives to an extent that member states must; but
also some of the EU member states. On the other hand, the report also reveals that
different criteria may exist across countries. This therefore leaves open the question
whether blood is indeed of a uniform standard across the EU and its surrounding
countries.
For instance, concerning donor eligibility criteria in EU member states for which
a certain specification had to be provided, there are about four different answers.
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Countries that provide a comprehensive account of exclusion criteria regarding risk-
laden sexual behavior usually specify these as homosexual relations, heterosexual
relations with changing partners, or unprotected intercourse, as well as intercourse
for drugs or money, often in connection with prostitution. In addition, sometimes
this risk group is expanded by excluding potential donors that have visited regions
with a high rate of HIV or hepatitis. Countries that have expanded the sexual-practice
deferral include Austria, Cyprus, Czech Republic, Denmark, France, Germany,
Lithuania, the Netherlands, Slovenia, Sweden, and the United Kingdom. Romania
forms a category by itself, listing the treatment for hemophilia before 1988 as the
criterion for exclusion. A third group is formed by countries that answer affirmatively
to whether exclusion criteria are in place (Finland, Greece, Hungary, Italy, Latvia,
Luxembourg, Malta, Poland, and Portugal). Finally, Bulgaria, the Republic of Ireland,
and Slovakia state that no national guidelines exist for the assessment of at risk
sexual behaviors.
Table 1 provides a comprehensive overview of EU member states’ testing require-
ments (excluding Estonia). The table reveals that there exists a consensual proce-
dure for testing requirements for three infectious agents (hepatitis B surface
antigen, anti-hepatitis C virus, and anti-HIV 1/2). However, apart from these three
tests, member states proceed unilaterally. Some even demand further tests to be
conducted, as specified in the table. Nonetheless, member states exchange blood
if they have the necessary procedures in place, which usually refers to the existence
of compatible safety standards in the country of origin, but may include regular on-
site inspections such as Germany demands. The exception is the United Kingdom,
which does not export blood or blood components because of variant Creutzfeldt-
Jakob disease risks. The report does not specify whether the reason is that the
United Kingdom refrains from exporting voluntarily or whether this is a consequence
of EU member states refusing to import blood from the United Kingdom. The latter
case might be the reason, judging from Germany’s policy to deny donations from
people who have spent more than 10 months in the United Kingdom between
1980 and 1996.
Apart from the special role of the United Kingdom, the EU forms a relatively closed
market for blood and blood components. Trade of components within the EU takes
place as long as bilateral agreements and comparable minimum standards exist.
However, trade in blood and blood products is not necessarily well documented,
meaning that there is usually a lack of data in terms of volumes exported (and, by
implication, imported). Greece claims to have imported 26,000 units of blood cells
from Switzerland, a non-EU member country, during 2008, while Sweden imports
plasma used as a source material for medicinal products from the United States.
On the other hand, Poland exported 107,032.5 L of plasma for fractionation to other
EU countries while Germany exported 1,136,060 L of plasma for fractionation without
specifying the destination. France exported 55 red blood cell concentrates and 6 fresh
frozen plasmas to 13 countries (Algeria, Belgium, Canada, Congo, Egypt, Gabon,
Germany, Hungary, Ireland, Mali, Nigeria, Senegal, and Switzerland).7
Possible Problems
The primary objective of the European Community was to establish a safe and reliable
supply of blood and blood products to citizens across Europe. A European Blood
Directive was developed and specified in cooperation with national and regional blood
establishments in the subsequent years. This effort resulted in the Mother Directive of
2002 and three directives that specified its content. Again, in practice, the specific
implementation arrangements were developed by practitioners, resulting inter alia in
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Table 1
Testing requirements in EU member states
Anti
HBc
HBs
ag
NAT
HBV
Anti
HCV
NAT
HCV
Anti
HIV-
1/2
Ag
HIV
NAT
HIV 1
Treponema
Pallidum HTLV Further Tests?
Austria U U U U U U Nonspecific immunactivating marker (eg,
neopterin)
Belgium U U U U U U Anti-HBc for new donors and on indication
Bulgaria U U U U U
Cyprus U U U U U CMV for immunosuppressed patients
Czech Republic U U U U U
Denmark U U U U U U Ua
Finland U U U U U U U According to the epidemiologic situation, extra
testing may be required
France U U U U U U U U U NAT HBV* In some French areas with particular
epidemiologic situations (French overseas
departments) Detection of malaria infectious
markers. If necessary (individuals who have
lived a malarial area or with history of
undiagnosed febrile illness, visitors to
endemic area)
Germany U U U U U U U
Greece U U U U U U U U
Hungary U U U U U
Rep. of Ireland U U U U U
H
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Italy U U U U U U U
Latvia U U U U U U U
Lithuania U U U U U U U U
Luxembourg U U U U U U U U ? U VDRL
Malta U U U U U Tests are required for: hemoglobin, liver
function, anti-CMV/parvovirus (on request)
Netherlands U U U U U U U U Parvo B19 for selected donations and bacterial
culture for all platelets
Poland U U U U U U U ALT
Portugal U U U U U U U U U U
Romania U U U U U HIV testing is performed using AG/antibody anti
HIV combined kits
Slovakia U U U U U U
Slovenia ? U U U U U U U U ? NAT, anti HIV1/2/0 and p24Ag, HIV RNA, HCV
RNA, HBV DNA are obligatory
Spain U U U U U U U Trypanosoma cruzi
Sweden U U U U U U Hemoglobin
United
Kingdom
U U U U U U Not for mandatory donor screening. Certain
additional tests may be performed,
depending on need, eg, anti-CMV
Abbreviations: Ag, antigen; ALT, alanine aminotransferase; Anti, antibody; CMV, cytomegalovirus; HBc, hepatitis B core antigen; HBs, hepatitis B surface; HCV,
hepatitis C virus; HTLV, human T-lymphotrophic virus; NAT, nucleic acid amplification technology.
a Only first time donors.
From European Commission. Summary table of responses from competent authorities for blood and blood components. Questionnaire on the transposition and
implementation of the European regulatory framework blood and blood components. Brussels, Health and Consumers Directorate-General; January 15, 2010.
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SOP handbooks. Meanwhile, EU member states have gradually transposed the Direc-
tive into national legislation where it is now one of standards to ensure the quality of
blood and its derivative products.
However, potential problems remain, pertaining to medical as well as political
issues. On the medical side, an assessment of the implementation questionnaire
reveals that different standards for testing requirements exist. Given that only three
common transmissible disease-testing requirements can be found across member
states, one wonders whether a uniform level of quality has been achieved. Another
indicator toward this conclusion can be found in the very different amount of detail
provided regarding data on import and export of blood and blood products between
member states or across EU borders. In a similar vein, Listl and Klouche1 state that
Directive 2004/33/EC is not specific enough in terms of the required bacteriologic
control, leaving the interpretation of the implication to member states.
The other, potentially more pressing, issue is political in nature. It concerns several
points. First, there is the problem of growth. During the period of developing the
different blood directives, the EU grew from 15 member states in 1995 to the current
number of 27. During any growth process, accession candidates are required to
accept the entire acquis communautaire, that is, the existing legal framework of
the EU. This might be a source of concern as new members may not yet have trans-
posed directives into national legislation and standards of safety might not be in
operation. Consequently, the tradability and availability of blood and blood products
might be hampered. Second, a concern arises from admission criteria that are
closely linked to citizens’ mobility throughout and out of the EU. As Listl and
Klouche1 write, criteria in Directive 2004/33/EC ‘‘lack explicit exclusion criteria for
several relevant parasitic infectious diseases, eg, mucocutaneous leishmaniosis or
trypanosomiasis, while other guidelines regarding for instance toxoplasmosis, do
only apply to blood but not to plasma destined for fractionation. In view of the occur-
rence of some of these infectious diseases in certain European countries, the contin-
uous presence of immigrants from endemic countries, and the extent of international
travel, these risks may not have received sufficient attention.’’8 Third, exclusion
criteria might run counter to EU regulations that not only seek to promote mobility
but also adhere to the principle of nondiscrimination. Although some countries
have explicitly excluded certain risk groups from donation, as noted previously,
a few member states have not. This might, one day, result in a ruling by the European
Court of Justice. Fourth, related to the previous point, eventually certain criteria
might reduce the pool of potential donors. Unforeseen risks may diminish the poten-
tial for interchangeability of blood and blood products, similar to the case of the
United Kingdom that does not export because of the risk of variant Creutzfeldt-Jakob
disease.
SUMMARY
These considerations amount to the insight that, despite the formulation of the Euro-
pean Blood Directive in 2002 and its subsequent implementation and specification,
blood policies in the EU remain a work in progress. Social and political developments
will require adjustments and specifications in the future. At the same time, policies
need to be devised to maintain a pool of (reliable) donors. As much as barriers
(read: exclusion criteria) might counteract this objective, a continuous effort into posi-
tively swinging public opinion toward donation seems needed. This is likely to involve
both the European Commission and practitioner organizations such as the EBA in the
near future.
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